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Abstract: The treatment of metastatic breast cancer (MBC) has become increasingly   challenging 
as the primary goals of therapy include prolonging life without added toxicity. While multiple 
agents are approved for the therapy of MBC, there is no standard approach for therapy beyond 
the second-line. Eribulin mesylate, an analog of the marine sponge halichondrin B, is a non-taxane 
microtubule dynamics inhibitor with a mechanism of action distinct from other tubulin-targeted 
drugs. Based on a significant extension in overall survival seen in a Phase III clinical trial, eribulin 
was approved for third-line therapy in MBC patients following anthracycline and taxane failure. 
Eribulin has a manageable toxicity profile and a low incidence of peripheral neuropathy. In this 
review, we discuss the natural source of eribulin, pharmacology, mode of action, preclinical and 
clinical data, and patient-focused perspectives.
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Introduction
Breast cancer is the most common malignancy affecting women worldwide. In 2011, 
an estimated 1,383,500 individuals will be diagnosed with breast cancer and 484,400 
will die from the disease.1 In the US alone, 5% of patients presenting with breast cancer 
will have metastatic disease, and 20% of patients with early-stage breast cancer will 
develop a recurrence over 10 years after adjuvant systemic treatment.2,3 Treating meta-
static breast cancer (MBC) has become increasingly complex, as oncologists attempt 
to strike a balance between prolonging survival and minimizing toxicity. Despite many 
available chemotherapeutic options, guidelines do not exist on how best to sequence or 
combine them. Moreover, there is little good quality evidence on later lines of therapy 
in women who fail two or more chemotherapeutic regimens.
Several chemotherapeutic agents have been approved for pretreated MBC and 
include capecitabine (Xeloda), ixabepilone (Ixempra), and most recently eribulin 
  mesylate (Halaven, E7389) based on Phase III data. Capecitabine, an oral fluoro-
pyrimidine, when administered with docetaxel, prolonged overall survival (OS) 
in anthracycline-pretreated MBC patients; the median OS was 14.5 months in the 
combination group vs 11.5 months in the docetaxel-treated group (HR: 0.775, 95% 
confidence interval [CI]: 0.634–0.947, P = 0.0126). Gastrointestinal side effects and 
hand-foot syndrome were more common in the capecitabine arm occurring in .60% 
of the patients.4 Ixabepilone, a microtubule-targeted epothilone analog, improved 
progression-free survival (PFS) in combination with capecitabine relative to capecit-
abine alone (median 5.8 vs 2.4 months, HR: 0.75, 95% CI: 0.64–0.88, P = 0.0003) in 
patients with MBC treated with anthracycline and taxane therapy. The ixabepilone 
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arm reported 66% neuropathy (22% grade 3/4) and 68% 
grade 3/4 neutropenia.5 A confirmatory trial similarly dem-
onstrated a significant improvement in PFS with ixabepilone 
plus capecitabine compared to capecitabine alone but not in 
OS, the primary endpoint of the study, except for patients 
with an impaired Karnofsy’s performance score (KPS) 
of 70% to 80%. Neutropenia (92% all grades, 72% grade 
3/4) was considerable though febrile neutropenia was 
uncommon (7%). Peripheral neuropathy in the ixabepilone 
group (66% all grades, 24% grade 3/4) led to study discon-
tinuation in 26% of patients but was reversible.6 In November 
2010, the US Federal Drug Administration (FDA) approved 
eribulin mesylate as third-line treatment for MBC refractory 
to anthracyclines and taxanes based on a Phase III clinical 
trial showing significantly increased overall survival com-
pared to treatment of investigator’s choice.7 Eribulin is the 
only drug to date that has been shown to prolong survival 
of heavily pretreated MBC patients when administered as 
monotherapy. That is, the survival benefit seen with both 
capecitabine and ixabepilone has never been investigated in 
adequately powered single-agent studies.
Introduction to eribulin
In 1986, Hirata and Uemura extracted halichondrin B, a large 
polyether macrolide, from a rare marine Japanese sponge, 
Halichondria okadai.8 Based on its potent anticancer activity 
in preclinical models, it was further evaluated in the National 
Cancer Institute drug evaluation program against other known 
antimitotic and cytotoxic drugs.9 The antiproliferative effects 
of halichondrin B were found to be similar to other antitubu-
lin agents but its mode of action was remarkably distinct.9,10 
Despite its impressive in vitro and in vivo anticancer activity, 
the natural source was not available in sufficient quantity for 
drug development. In 1998, the biologically active part of 
the drug was discovered to reside in the macrocyclic lactone 
C1-C38 moiety, and a completely synthetic and structurally 
simplified derivative with retained high potency of its parent 
compound was developed.10,11
Eribulin: pharmacology  
and mechanism of action
Eribulin inhibits cancer cell proliferation by binding tubulin 
and destabilizing microtubule dynamics.12 At nanomolar 
concentrations, eribulin works through an end-poisoning 
mechanism by inhibiting the growth phase of microtubule 
dynamic instability in interphase cells. Tubulin is sequestered 
into nonfunctional aggregates, leading to an   irreversible 
arrest at G2-M phase and ultimately apoptosis after   prolonged 
mitotic blockade. Other anti-microtubule agents such as 
paclitaxel and vinblastine induce mitotic blockade and apop-
tosis in cancer cells similar to eribulin, however the precise 
interactions between eribulin and tubulin were found to be 
unique. By binding to the interdimer interface or the β-tubulin 
subunit alone, eribulin inhibits only microtubule growth with 
no effect on shortening, while taxanes and vinca alkaloids 
suppress both the growth and shortening phases of micro-
tubule dynamic instability.10,12–16 This novel tubulin-based 
mechanism of eribulin may explain its ability to overcome 
taxane resistance and have wider anti-cancer activity both 
in the lab and in the clinic.
The mechanistic basis for the anticancer effects of 
eribulin was demonstrated in eribulin-treated human lym-
phoma and prostate cancer cell lines. Increasing numbers 
of hypodiploid cells were seen after eribulin treatment, sug-
gesting the initiation of apoptosis after prolonged mitotic 
blockade. Biochemical correlates of apoptosis revealed 
phosphorylation of the anti-apoptotic protein Bcl-2, mito-
chondrial cytochrome c release, proteolytic activation 
of caspase-3 and -9, and cleavage of the caspase-3 sub-
strate poly (ADP-ribose) polymerase (PARP). Detection 
of   cytochrome c and caspase-9 after eribulin treatment 
indicated that the mitochondrial apoptotic pathway was 
activated, a mechanism most commonly associated with 
chemotherapy response.15
The pharmacokinetics of eribulin is linear and dose-
dependent with a rapid volume of distribution of 48 L/m2 
to 114 L/m2, slow to moderate clearance of 1.16 L/hour/m2 
to 2.42 L/hour/m2, and slow triphasic elimination with a 
  prolonged terminal half-life ranging from 34 to 48 hours 
over the dose range of 0.25 to 1.4 mg/m2. Pharmacokinetic 
profiles were similar between day 1 and day 8 doses. At the 
maximum tolerated dose (MTD), plasma levels of eribulin 
were above concentrations required for in vitro cytotoxicity 
for .1 week. Renal excretion is minimal with 5%–11% of 
the administered dose recovered in the urine.17–19 A Phase I 
trial in patients with renal dysfunction (20–40 mL/minute, 
  Cockroft–Gault, not requiring dialysis) demonstrated toler-
ance at full doses of eribulin.20 Conversely, in a dedicated 
hepatic impairment study, liver dysfunction decreased 
clearance and prolonged elimination half-life, resulting 
in increased eribulin   exposure. Though eribulin was well 
tolerated and safe in this study, hepatic impairment war-
rants adjustment of eribulin dosing.21 Metabolism of eribu-
lin is minimal and there are no major human metabolites 
of   eribulin. While eribulin is primarily metabolized by 
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at clinically relevant concentrations in vitro nor affect the 
metabolism of other CYP3A4-mediated agents including 
tamoxifen and paclitaxel.22 A drug–drug interaction trial 
demonstrated that ketoconazole, a strong CYP3A4 inhibitor, 
did not affect eribulin clearance.23 Eribulin is also a substrate 
and weak inhibitor of the P-glycoprotein (PgP) drug efflux 
transporter, with less sensitivity to PgP-mediated multidrug 
resistance in vitro.24
Preclinical studies
Eribulin has impressive in vitro and in vivo activity with 
similar potency to its natural parent compound. Eribulin 
demonstrated in vitro inhibition at sub-nanomolar concentra-
tions against several human cancer cell lines including breast 
cancer (MDA-MB-435), colon cancer (COLO 205, DLD-1), 
and prostate cancer (LNCaP, DU 145) with greater potency 
than vinblastine and paclitaxel. When eribulin was tested 
in vivo in the 0.05–1 mg/kg range against human tumor 
xenograft models including breast, colon, and ovarian cancer, 
significant anti-tumor effects were achieved. Complete tumor 
regressions and long-term suppression of tumor regrowth 
were observed. Notably, the in vivo therapeutic window of 
eribulin was unusually wide for a cytotoxic drug, with .95% 
tumor suppression over a four-fold dosing range without 
evidence of toxicity. Eribulin showed superior efficacy at 
lower doses compared to paclitaxel at empirically determined 
MTD.10 Moreover, eribulin retained essentially full in vitro 
potency in paclitaxel-resistant human ovarian cancer cell 
lines harboring β-tubulin mutations, suggesting that eribulin 
may be effective in taxane-refractory disease.14 In breast 
cancer cell lines, a significant correlation was demonstrated 
between higher levels of βIII-tubulin expression, which is 
associated with resistance to tubulin-targeted agents, and 
sensitivity to eribulin.25
Phase I studies
The remarkable preclinical activity of eribulin led to the 
clinical evaluation of eribulin in a variety of tumor types 
(Table 1). Reported in abstract form, the California Cancer 
Consortium completed the first Phase I trial with eribulin, 
using a rapid titration design with real-time   pharmacokinetics 
(PK) to guide dose escalation. Forty patients with refractory 
or advanced solid tumors were enrolled and 38 patients 
received eribulin as a weekly 1–2 minute intravenous (IV) 
bolus three of 4 weeks, starting at 0.125 mg/m2/week. Patients 
were continued on a standard 3 × 3 dose escalation schedule 
until grade 2 or higher toxicities were observed. Median 
age was 61 years, and KPS was greater than 70% in 31 of 
38 patients. The most common primary tumor sites were lung 
(nine patients) and breast (four). Rapid escalation ended with 
a grade 3 alkaline phosphatemia at 0.5 mg/m2/week. Two 
dose-limiting toxicities (DLT) occurred at 2.0 mg/m2/week 
including one grade 3 febrile neutropenia and one grade 4 
neutropenia. Consequently, the MTD was 1.4 mg/m2/week. 
Other serious nonhematologic toxicities included hypoglyce-
mia, hypophosphatemia, and fatigue. Responses included two 
partial responses (lung, bladder) and three minor responses 
(lung, breast, and thyroid). Stable disease as best response 
was reported in 12 patients lasting a median of 4 months 
(range 2–14). Fluorescent immunohistochemical analysis 
of serial tumor biopsies in 13 patients treated at the MTD 
demonstrated disruption of microtubule structure in vivo 
with eribulin treatment.17
A subsequent Phase I trial reported by Goel et al18 enrolled 
patients with advanced solid malignancies. Eribulin dosing 
began at 0.25 mg/m2 over 1 hour on days 1, 8, and 15 of a 
28-day cycle with escalation guided by DLTs. Thirty-two 
patients received eribulin (0.25, 0.5, 0.7, 1.0, or 1.4 mg/m2). 
Patients had received a median of two prior   chemotherapeutic 
Table 1 Review of Phase i clinical trials of eribulin in advanced solid tumors
Author n Treatment RR, n (%) SD, n (%) Dose-limiting toxicities
Synold et al17 40 eribulin 0.125–2 mg/m2 over 2 minutes on days  
1, 8, 15 every 28 days
2 (5) 12 (32) Febrile neutropenia, neutropenia
Goel et al18 32 eribulin 0.25–1.4 mg/m2 over 1 hour on days  
1, 8, 15 every 28 days
1 (3) 10 (31) Neutropenia
Tan et al19 21 eribulin 0.25–4 mg/m2 over 1 hour every 21 days 1 (5) 12 (57) Febrile neutropenia, neutropenia
Minami et al26 15 eribulin 0.7–2 mg/m2 over 5 minutes on days  
1 and 8 every 21 days
3 (20) 3 (20) Febrile neutropenia, neutropenia
Goel et al27 21 eribulin 0.7–1.4 mg/m2 with gemcitabine  
800–1000 mg/m2 on days 1, 8, 15 every 28 days.  
Due to DLT, changed to days 1 and 8 every 21 days
1 (5) 8 (38) Grade 3 diarrhea, dizziness,  
fatigue
Swami et al28 52 eribulin 0.7–1.4 mg/m2 over 2–5 minutes on days 1 and 8 
with carboplatin AUC 5–6 on day 1 every 21 days.
3 (6) NR Febrile neutropenia, neutropenia
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regimens (range 1–13), of which 62.5% had prior vinca 
  alkaloid or taxane treatment. The principal DLT was 
  neutropenia at 1.4 mg/m2 observed in two patients with 
grade 4 neutropenia, one of whom developed grade 3 fatigue. 
Three additional patients developed grade 3 neutropenia, 
and the day 15 treatment of cycle 1 was not given. Thus, 
the MTD was determined as 1.0 mg/m2.   Overall, eribulin 
showed a manageable toxicity profile with the most common 
eribulin-related adverse effects due to fatigue (53% overall, 
13% grade 3, no grade 4), nausea (41%, all grade 1/2), 
and anorexia (38% overall, 3% grade 3, no grade 4). Eight 
patients (25%) reported grade 1/2 neuropathy, and no grade 
3/4 neuropathy events were seen. Responses included stable 
disease in ten patients, ranging from 39 to 234 days, and an 
unconfirmed partial response in one patient with cervical 
cancer, lasting 79 days.18
Tan et al19 reported a similar Phase I trial of eribulin 
administered to 21 patients with advanced solid tumors. 
Eribulin was given as a 1-hour IV infusion every 21 days 
using an accelerated titration design at doses of 0.25, 0.5, 1, 
2, 2.8, and 4 mg/m2. All three patients experienced a DLT 
of febrile neutropenia at the 4 mg/m2 dose level. The dose 
was reduced to 2.8 mg/m2, in which two of three patients 
developed febrile neutropenia. At 2 mg/m2, one of seven 
patients experienced a neutropenic DLT, and this dose level 
was defined as the MTD. Grade 3/4 neutropenia occurred in 
33% at 7–15 days after the first treatment with recovery to 
normal by the end of the 21-day cycle. Twenty-four percent 
of patients developed a grade 1 anemia at doses greater 
than 0.5 mg/m2. Eleven patients received growth factor sup-
port. The most frequently reported nonhematologic drug-
related adverse effects were alopecia (33%), fatigue (33%, 
all grade 1/2), nausea (19%, all grade 1), and anorexia (14%, 
all grade 1/2). Notably, neuropathy was not predominant 
in this study with only one patient in the 4 mg/m2 cohort 
experiencing a grade 1 neuropathy. Seven patients developed 
nine serious adverse effects including one case of grade 3 
hyponatremia, one case of grade 3 infection, and six cases 
of grade 4 febrile neutropenia. Though there were no com-
plete responses, 12 patients experienced stable disease for 
a median duration of 86 days (range 47 to 386). Of these 
12 patients, four had received prior taxane treatment. One 
patient with non-small cell lung cancer with no prior taxane 
exposure achieved an unconfirmed partial response after four 
cycles of eribulin at the 4 mg/m2 dose. One patient died of 
progressive disease.19
Minami et al reported a Phase I study in Japanese patients 
with refractory solid cancers. Fifteen patients received   eribulin 
as a 2–10 minute IV bolus in doses ranging 0.7–2.0 mg/m2 on 
days 1 and 8 of a 21-day cycle. Patients were extensively pre-
treated with a median of 4 (range 1–7) prior chemotherapeutic 
regimens; 47% had received taxane therapy. The principal 
DLT was neutropenia, observed in all three patients treated 
at 2.0 mg/m2 and in all six patients at 1.4 mg/m2. Two of 
three patients developed grade 3 febrile neutropenia in the 
2.0 mg/m2 and three of six patients in the 1.4 mg/m2 cohort, 
establishing the MTD as 2.0 mg/m2 and the recommended 
dose for Phase II studies as 1.4 mg/m2. All neutropenic events 
were reversible, and the schedule of administering eribulin 
on days 1 and 8 of a 21-day cycle allowed sufficient time for 
resolution of grade 3/4 neutropenia prior to the next cycle. 
Most common nonhematologic toxicities included fatigue 
(33% overall, 13% grade 3, no grade 4), hyperglycemia 
(40% all grade 2), and alopecia (20% all grade 2). Partial 
responses were seen in three patients at the 1.4 mg/m2 dose 
level. Stable disease was observed in four patients including 
two with breast cancer.26
Phase I studies combining eribulin with a cytotoxic drug 
were also undertaken. Twenty-one patients with advanced 
solid tumors received eribulin and gemcitabine. One par-
tial response in an ovarian cancer patient was seen. Stable 
disease was achieved in eight patients (38%). DLTs were 
grade 3 diarrhea, dizziness, and fatigue. Grade 3/4 hematologic 
toxicities included neutropenia (29%) and   thrombocytopenia 
(10%). The doses recommended for Phase II studies were 
eribulin 1.0 mg/m2 and   gemcitabine 1000 mg/m2 every 
3 weeks.27 In a Phase II study, 52 patients with advanced 
solid malignancies received eribulin and   carboplatin. DLTs 
included febrile neutropenia and   neutropenia. Most fre-
quent grade 3/4 adverse events were neutropenia (40%), 
thrombocytopenia (13%), and fatigue (4%). One complete 
response was observed in tonsillar cancer and two partial 
responses in prostate cancer. The recommended doses for 
further Phase II investigation were eribulin 1.1 mg/m2 and 
carboplatin AUC 6.28
In these Phase I trials, eribulin demonstrated a manage-
able toxicity profile and promising anti-cancer activity. 
Neutropenia was the main DLT despite variations in dosing 
and administration but was easily reversible.
Phase II studies in MBC
Three Phase II trials were subsequently conducted in women 
with heavily pretreated breast cancer (Table 2). Vahdat et al 
reported a single-arm, open-label, multicenter Phase II study 
enrolling 103 patients with MBC with previous anthracycline 
and taxane therapy. Eribulin 1.4 mg/m2 was administered Biologics:   Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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as an IV infusion over 2–5 minutes on days 1, 8, and 15 
of a 28-day cycle. An assessment of toxicity indicated that 
patients were experiencing neutropenia on day 15, and a 
second cohort of 33 patients received eribulin, only on days 1   
and 8 of a 21-day cycle. The primary endpoint was objec-
tive response rate (ORR). The median age was 55, and 54% 
of patients had an Eastern Cooperative Oncology Group 
(ECOG) performance status of one at baseline. Patients 
had received extensive treatment with a median of four 
prior chemotherapy regimens (range 1–11). Patients in the 
28-day cohort received a median of 2.5 cycles of eribulin 
compared with a median of 4 in the 21-day cohort. In the 
28-day cohort, 63% of patients experienced dose interrup-
tions, delays, reductions, or omissions primarily due to 
neutropenia during cycle 1, compared to 18% of patients in 
the 21-day cohort. Eighty-seven patients who met the key 
inclusion criteria were included in the per protocol (PP) 
population. In the PP population, the ORR by independent 
review was 10.2% and 14.3% in the 28- and 21-day cohorts, 
respectively, yielding an overall ORR of 11.5% (95% CI: 
5.7–20.1). In the intent-to-treat (ITT) population, the ORR 
was 13.6% (95% CI: 7.6–21.8) by independent review. The 
clinical benefit rates (CBR), defined as complete and partial 
responses plus stable disease for $6 months, in the 28- and 
21-day cohorts were 11.9% and 28.6%, respectively, yield-
ing an overall CBR of 17.2% (95% CI: 10.0–26.8) in the PP 
population. The median duration of response was 5.6 months 
(range 1.4–11.9). The median PFS was 2.6 months (range 
0.03–14.9) and the 6-month PFS rate was 25.9% (95% CI: 
15.5–36.3). The median OS was 9.0 months (range 0.5–27.1). 
The 6-month and 1-year survival rates were 67.8% (95% CI: 
58.0–77.6) and 45.7% (95% CI: 35.2–56.2), respectively. 
In exploratory analysis, eribulin appeared to have activity 
across all subgroups including those treated with four or 
more regimens.29
The most frequent toxicities included neutropenia (75% 
overall, 64% grade 3/4), fatigue (52% overall, 5% grade 3, 
no grade 4), nausea (37% overall, 1% grade 3, no grade 4), 
and anorexia (15%, only grade 1/2). The incidence of febrile 
neutropenia was low, only occurring in 4% of patients. 
  Fifty-three percent and 50% of patients received erythrocyte 
and granulocyte growth factors, respectively. Forty-one 
  percent of patients reported alopecia, however the presence of 
alopecia at baseline was not recorded. Only five patients (5%) 
experienced grade 3 peripheral neuropathy, of which four 
were in the 28-day cohort. No grade 4 neuropathy events were 
reported. Overall, the 21-day schedule appeared to be better 
tolerated than the 28-day schedule, with less   neuropathy, 
anorexia, anemia, and thrombocytopenia.29
Cortes et al reported a subsequent single-arm, open-label, 
multicenter Phase II trial of eribulin enrolling 299 patients 
with locally advanced and MBC who had previously received 
an anthracycline, taxane, and capecitabine. Eribulin 1.4 mg/m2 
was administered as a 2–5 minute IV infusion on days 1 and 8 
of a 21-day cycle to 291 patients. The primary end point was 
ORR. Patients were extensively pretreated with a median of 
four chemotherapy regimens. The median age was 56, and 
63% had an ECOG score of 1 or 2. Patients received a median 
of four cycles (range 1–27). Of the 291 patients treated with 
eribulin, 21% experienced treatment delays, 8.6% expe-
rienced dose omissions, and 3.4% had dose reductions in 
cycle 1, primarily due to   neutropenia. This low number of 
dose reductions suggested that the 21-day dosing schedule 
was more optimal than the 28-day dosing schedule used in 
the prior Phase II study. In the 269 patients who met the key 
inclusion criteria for primary efficacy analysis, the indepen-
dently reviewed ORR was 9.3% (95% CI: 6.1–13.4) and the 
CBR was 17.1% (95% CI: 12.8–22.1). In the ITT population, 
the independently reviewed ORR and CBR were 9.3% (95% 
CI: 6.2–13.2) and 17.2% (95% CI: 13.0–22.0), respectively. 
Table 2 Summary of Phase ii trials of eribulin in metastatic breast cancer
Study Protocol  
population
ORR (%) SD (%) Median PFS  
(months)
Median OS  
(months)
Grade 3/4 adverse events
vahdat et al29 87 11.5 42.5 2.6 9 Neutropenia (64%), febrile neutropenia 
(4%), fatigue (5%)*, peripheral 
neuropathy (5%)*
Cortes et al30 269 9.3 46.5 2.6 10.4 Neutropenia (54%), febrile neutropenia 
(6%), fatigue (10%)*, peripheral 
neuropathy (7%)*
iwata et al31 81 21.3 37.5 3.7 10.9 Neutropenia (95%), febrile neutropenia 
(14%), peripheral neuropathy (4%)*
Note: *No grade 4 events.
Abbreviations: ORR, overall objective response rate (CR + PR); SD, stable disease; PFS, progression-free survival; OS, overall survival; CR, complete response; PR, partial 
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The median   duration of response was 4.1 months (range 
1.4–8.5). The median PFS was 2.6 months (range 0.03–13.1), 
and the 6-month PFS rate was 15.6% (95% CI: 10.7–20.5). 
The median OS was 10.4 months (range 0.6–19.9), and the 
6-month OS rate was 72.3% (95% CI: 66.9–77.6). There 
was activity across all subgroups, with higher responses in 
less refractory patients and in hormone receptor positive 
disease. The most common eribulin-related adverse events 
were   neutropenia (60% overall, 54% grade 3/4), fatigue 
(65% overall, 10% grade 3, no grade 4), and nausea (44% 
overall, 2% grade 3, no grade 4). Febrile neutropenia occurred 
in 5.5% of patients. Only 7% of patients reported grade 3 
peripheral neuropathy, with no grade 4 incidences. Eribulin 
did not exacerbate pre-existing grade 1/2 neuropathy.30
Another single-arm, open label Phase II study, reported 
by Iwata et al31 in abstract form, enrolled 84 Japanese 
patients with locally advanced or MBC previously treated 
with an anthracycline and a taxane. Of the 81 patients who 
received eribulin 1.4 mg/m2 as a 2–5 minute IV infusion on 
days 1 and 8 of a 21-day cycle, the primary endpoint ORR 
was 21.3% (95% CI: 12.9–31.8). There were no complete 
responses and 17 partial responses. Stable disease was 
seen in 37.5% of patients. The median duration of response 
was 3.7 months (95% CI: 2.8–4.9). The median PFS was 
3.7 months (95% CI: 2.0–4.4) and 6-month PFS rate was 
20.1%. The median OS was 10.9 months and the 6-month 
OS rate was 72.3%. The most frequent treatment-related 
grade 3/4 toxicities were neutropenia (95%), leukopenia 
(74%), and febrile neutropenia (14%). Grade 3 peripheral 
neuropathy occurred in 3.7% of patients (no grade 4).31
These Phase II studies demonstrated that eribulin was 
active in a heavily pretreated breast cancer population. 
  Toxicities recapitulated those seen in the Phase I studies.
Phase III studies in MBC
The Phase III trial, Eisai Metastatic Breast Cancer Study 
Assessing Physician’s Choice Versus E7389 (EMBRACE; 
E 305, NCT00388726) was a global, multicenter, open-
label, randomized study which established eribulin as a new 
potential standard treatment for heavily pretreated MBC 
(Table 3).7 In this study, 762 women with locally recurrent 
or MBC were randomly allocated in a 2:1 ratio to eribulin 
1.4 mg/m2 over 2–5 minutes on days 1 and 8 of a 21-day cycle 
(n = 508) or treatment of physician’s choice (TPC; n = 254). 
  Randomization was stratified by geographical region, previous 
capecitabine treatment, and human epidermal growth factor 
receptor 2 (HER2) status. TPC was defined as any single-
agent chemotherapy, hormonal, or biologic treatment, or best 
supportive care alone. Tumor assessments were evaluated 
according to Response Evaluation Criteria in Solid Tumors 
(RECIST) every 8 weeks, or sooner if disease progression 
was suspected. The primary endpoint was overall survival in 
the ITT population.
The median age was 55 years (range 27–85), and majority 
of patients (49%) had an ECOG score of one. Patients were 
extensively pretreated, having received a median of four prior 
chemotherapy regimens (range 1–7) including an anthracy-
cline and a taxane, unless contraindicated. Most were con-
sidered refractory to taxanes (81% of patients), capecitabine 
(68%), and/or anthracyclines (58%), defined as progression 
on or within 6 months of receiving treatment. Overall, 16% 
of patients had HER2-positive breast cancer and 19% had 
triple-negative (ER-negative, PR-negative, HER2-negative) 
disease. The most common metastatic sites were bone (61% 
of patients) and liver (60%), and 51% had at least three organ 
sites involved. Most TPC patients received chemotherapy 
(96%) including vinorelbine (26%), gemcitabine (18%), 
Table 3 Results of Phase iii eMBRACe trial
Eribulin TPC P value
Intent-to-treat population, n 508 254
Median OS (months) 13.1 10.6 0.04
95% Ci 11.8–14.3 9.3–12.5
Median PFS (months) 3.7 2.2 0.137
95% Ci 3.3–3.9 2.1–3.4
Response evaluable population, n 468 214
Objective response rate (CR + PR), % 12.2 (9.4–15.5) 4.7 (2.3–8.4) 0.002
Clinical benefit rate (CR + PR + SD $ 6 months ), % 23 (18.9–26.7) 17 (12.1–22.5)
Common grade 3/4 toxicities (%)
Neutropenia (febrile neutropenia) 45 (5) 21 (2)
Asthenia/fatigue 9 10*
Peripheral neuropathy 8 2*
Note: *No grade 4.
Abbreviations: SD, stable disease; PFS, progression-free survival; OS, overall survival; CR, complete response; PR, partial response.Biologics:   Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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capecitabine (18%), taxanes (15%), and anthracyclines 
(10%) representing real-life treatment decisions at the time 
(2006–2008). Four percent received sole hormone therapy 
and no patients received supportive care alone. The median 
duration of eribulin treatment and TPC was 3.9 months 
(range 0.7–16.3) and 2.1 months (range 0.03–21.2) for those 
receiving chemotherapy, respectively. Dose interruptions, 
delays, or reductions occurred in 421 (84%) patients in the 
eribulin group compared to 182 (76%) in the chemotherapy 
TPC groups, primarily due to neutropenia.
The study met its primary endpoint, showing a   significant 
increase in OS for eribulin (13.1 months, 95% CI: 11.8–14.3) 
compared with TPC (10.6 months, 95% CI: 9.3–12.5; HR: 
0.81, 95% CI: 0.66–0.99, P = 0.041) in the ITT   population. 
The median PFS in the eribulin-treated and the TPC groups 
was 3.7 months (95% CI: 3.3–3.9) and 2.2 months (range 
2.1–3.4), respectively (HR: 0.87, 95% CI: 0.71–1.05, 
P = 0.137) by independent review. Investigator assess-
ment demonstrated a similar but significant median PFS 
(HR: 0.76, 95% CI: 0.64–0.90, P = 0.002), likely due to less 
censored patients with the investigator versus independent 
review (127 vs 241), resulting in more progression events 
with investigator assessment (635 vs 521). The PP popula-
tion revealed significant improvements in PFS with eribulin 
treatment in both independent and investigator reviews. The 
ORR with eribulin was 12% (95% CI: 9.4–15.5) compared 
to 5% (95% CI: 2.3–8.4) with TPC (P = 0.002) by inde-
pendent review. The CBR similarly favored eribulin (23%, 
95% CI: 18.9–26.7) over TPC (17%, 95% CI: 12.1–22.5). 
Three patients in the eribulin group experienced a complete 
response, and none were seen with TPC. Exploratory sub-
group analyses did not find any important differences in 
clinical efficacy except for a significantly longer survival 
for patients treated in North America, Western Europe, and 
Australia.
Eribulin was well tolerated consistent with earlier   studies. 
Though adverse events occurred in 99% of patients receiving 
eribulin, the majority was grade 1 or 2. Frequent toxicities 
included neutropenia (eribulin, 52% vs TPC, 30%), fatigue 
(54% vs 40%), nausea (35% vs 28%), and peripheral neu-
ropathy (35% vs 16%). Granulocyte colony stimulating 
factor was given to 18% in the eribulin group and 8% in 
the TPC group. Febrile neutropenia was uncommon (5% 
with eribulin vs 2% with TPC). Whereas ,1% of patients 
discontinued eribulin due to hematologic toxicity, peripheral 
neuropathy led to eribulin discontinuation in 5% of patients. 
  Nonetheless, neuropathy improved to grade 2 or lower after 
delays or dose reductions of eribulin in patients with grade 
3 or 4 neuropathy. The incidence of neuropathy with eribulin 
was similar to the taxane subgroup.
EMBRACE has been the only Phase III study in MBC to 
define OS as the primary endpoint and meet it. Furthermore, 
no study in MBC has included such a heavily pretreated 
population. Based on the 2.5 month extension of median 
survival representing a 23% increase in survival with   eribulin 
over TPC alongside a manageable side effect profile, the 
authors concluded that eribulin could become a potential 
new standard of care for heavily treated MBC patients. The 
results of this study led to the regulatory approval of eribulin 
in the US as third-line treatment of MBC after anthracycline 
and taxane failure.7 A subsequent Phase III trial (E 301) 
completed accrual of 1102 patients with locally advanced 
or MBC previously treated with anthracylines or taxanes, 
comparing eribulin to capecitabine. The primary endpoints 
are OS and PFS. Results are awaited.32
Patient-focused perspectives
Eribulin was well tolerated by breast cancer patients. The 
majority of dose reductions, delays, or omissions were due 
to neutropenia rather than clinical symptoms. Peripheral 
neuropathy remains a concern facing breast cancer patients 
and treating oncologists alike, as the incidence and severity 
tend to be cumulative and no standard therapy for prevention 
or management exists. Other microtubule-targeted agents 
used in the management of breast cancer, including the 
  taxanes and epothilones, are fraught with the development of 
severe (grade 3/4) neuropathy in as many as 30% of patients 
during their treatment course.33 Eribulin was associated 
with a low incidence of neuropathy in breast cancer clinical 
trials (27%–35% all grades, 3%–8% grade 3/4) though it is 
important to note that patients with pre-existing neuropathy 
above grade 2 were excluded from these trials.7,29,30 Eribulin 
did not appear to worsen pre-existing grade 1 or 2 peripheral 
neuropathy.30 Interestingly, mouse models demonstrated that 
eribulin induced less neuropathy than paclitaxel or ixabepi-
lone at equivalent MTD-based doses.34 The impact of eribulin 
versus ixabepilone on neuropathy is being investigated in 
MBC patients with prior taxane use (ClinicalTrials.gov 
identifier: NCT00879086). Eribulin also has a short infu-
sion time and does not require premedications to prevent 
hypersensitivity reactions.
Exploratory analysis of QOL parameters from the 
Phase II MBC study indicated no deterioration or improve-
ment in symptomatology among patients whose tumors 
responded to eribulin, although patients with progression 
experienced a marked symptomatic deterioration by the end Biologics:   Targets and Therapy 2012:6 submit your manuscript | www.dovepress.com
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of treatment.30 Due to the design of the EMBRACE Phase III 
study, it was not possible to capture QOL data, therefore it 
is difficult to assess if the adverse effects experienced by the 
patients was balanced by the 2.5-month survival extension. 
The E 301study comparing second-line eribulin to capecit-
abine in MBC patients includes a formal QOL assessment 
as a secondary objective.32
Conclusion
Eribulin has demonstrated remarkable Phase III clinical activ-
ity for the treatment of MBC refractory to an anthracycline and 
a taxane. Its unique mechanism of action likely enhances its 
ability to overcome chemo-resistance.   Furthermore, eribulin 
has a manageable side effect profile, a low incidence of periph-
eral neuropathy, tolerance at full doses in renal dysfunction, 
and lack of drug–drug interactions or   hypersensitivity. Several 
clinical trials evaluating eribulin in locally recurrent or MBC 
as monotherapy and in combination with biologic agents are 
ongoing (Table 4).35 Eribulin is also being investigated in Phase 
II studies of early stage breast cancer, eg, dose dense doxoru-
bicin and cyclophosphamide followed by eribulin in HER2-
positive disease (NCT01328249) and neoadjuvant eribulin and 
carboplatin in triple-negative patients (NCT01372579).
Eribulin has demonstrated clinical efficacy in several 
other malignancies including non-small cell lung cancer, 
urothelial tract cancer, and sarcoma.36–38 Active trials in 
advanced lung cancer include eribulin in combination with 
pemetrexed (NCT01126736) and erlotinib (NCT01104155) 
in previously treated disease, as well as first-line eribulin as 
monotherapy (NCT00400829). The safety of eribulin in renal 
dysfunction is being further studied in patients with meta-
static urothelial tract cancer (NCT00365157). A randomized, 
open-label, multicenter, Phase III trial is investigating eribulin 
and dacarbazine in soft tissue sarcomas (NCT01327885). 
To help guide future studies, the identification of predictive 
biomarkers is sorely needed. Nonetheless, eribulin has 
become an important addition to the breast cancer treatment 
armamentarium.
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